摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

butyryl‐L‐carnitine | 25518-46-1

中文名称
——
中文别名
——
英文名称
butyryl‐L‐carnitine
英文别名
O-n-Butyryl-carnitin;n-Butyryl-D(+)-carnitin [German];(3S)-3-butanoyloxy-4-(trimethylazaniumyl)butanoate
butyryl‐L‐carnitine化学式
CAS
25518-46-1
化学式
C11H21NO4
mdl
——
分子量
231.292
InChiKey
QWYFHHGCZUCMBN-VIFPVBQESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    16
  • 可旋转键数:
    7
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.82
  • 拓扑面积:
    66.4
  • 氢给体数:
    0
  • 氢受体数:
    4

文献信息

  • Method for normalization in metabolomics analysis methods with endogenous reference metabolites
    申请人:BIOCRATES Life Sciences AG
    公开号:EP2270699A1
    公开(公告)日:2011-01-05
    The present invention relates to the use of endogenous reference metabolites and a method for normalization of intensity data corresponding to amounts and/or concentrations of selected target metabolites in a biological sample of a mammalian subject, wherein said intensity data are obtained by a metabolomics analysis method with one or a plurality of endogenous reference metabolites, comprising carrying out at least one in vitro metabolomics analysis method of said selected target metabolites in said biological sample, simultaneously carrying out in the same sample a quantitative analysis of one or a plurality of endogenous reference metabolites or derivatives thereof, wherein said endogenous reference metabolites are such compounds in the biological sample which are present in the subject at an essentially constant level; and wherein said endogenous reference metabolites or derivatives thereof have a molecular mass less than 1500 Da.
    本发明涉及内源参比代谢物的使用以及对哺乳动物受试者生物样本中选定目标代谢物的量和/或浓度对应的强度数据进行归一化的方法,其中所述强度数据是通过一种或多种内源参比代谢物的代谢组学分析方法获得的、包括对所述生物样本中的所述选定目标代谢物进行至少一种体外代谢组学分析方法,同时对同一样本中的一种或多种内源性参考代谢物或其衍生物进行定量分析,其中所述内源性参考代谢物是生物样本中的化合物,它们以基本恒定的水平存在于受试者体内;所述内源性参考代谢物或其衍生物的分子质量小于 1500 Da。
  • Method of diagnosing and treating asphyxia
    申请人:InfanDx AG
    公开号:US11313866B2
    公开(公告)日:2022-04-26
    A method for in vitro diagnosing asphyxia and disorders related thereto, a method of in vitro estimating duration of hypoxia in a patient subjected to asphyxia, and a method for in vitro monitoring of normoxic, hypoxic and hyperoxic conditions and/or normobaric and hyperbaric oxygen therapy, includes quantitatively detecting in a biological sample of a patient a plurality of asphyxia specific endogenous compounds which are selected from the group consisting of biogenic amines; carnitine-derived compounds; amino acids; bile acids; carboxylic acids; eicosanoids; lipids; precursors of cholesterol, cholesterol metabolites; prostanoids; and sugars.
    一种体外诊断窒息和相关疾病的方法,一种体外估计窒息患者缺氧持续时间的方法,以及一种体外监测常氧、缺氧和高氧条件和/或常压氧和高压氧治疗的方法,包括定量检测患者生物样本中多种窒息特异性内源性化合物,这些化合物选自由生物胺组成的组;氨基酸、胆汁酸、羧酸、二十酸、脂类、胆固醇前体、胆固醇代谢物、前列腺素和糖类。
  • SUBSTRATES AND INTERNAL STANDARDS FOR MASS SPECTROSCOPY DETECTION
    申请人:Perkinelmer Las, Inc.
    公开号:EP1999270A2
    公开(公告)日:2008-12-10
  • Method of diagnosing asphyxia
    申请人:InfanDx AG
    公开号:EP2249161B1
    公开(公告)日:2020-05-13
  • METHOD OF DIAGNOSING ASPHYXIA
    申请人:InfanDx AG
    公开号:EP2427773B1
    公开(公告)日:2016-07-06
查看更多